Puma Total Stockholder Equity from 2010 to 2026
| PBYI Stock | USD 7.60 0.08 1.04% |
Total Stockholder Equity | First Reported 2007-09-30 | Previous Quarter 115.3 M | Current Value 130.3 M | Quarterly Volatility 72.6 M |
Check Puma Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Puma Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 5.8 M, Other Operating Expenses of 181.4 M or Operating Income of 39.2 M, as well as many indicators such as Price To Sales Ratio of 1.37, Dividend Yield of 0.0 or PTB Ratio of 2.17. Puma financial statements analysis is a perfect complement when working with Puma Biotechnology Valuation or Volatility modules.
Puma | Total Stockholder Equity | Build AI portfolio with Puma Stock |
The Total Stockholder Equity trend for Puma Biotechnology offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Puma Biotechnology is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Puma Biotechnology's Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Puma Biotechnology over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Puma Biotechnology's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Puma Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 74,404,441 | |
| Geometric Mean | 40,197,894 | |
| Coefficient Of Variation | 89.28 | |
| Mean Deviation | 52,625,990 | |
| Median | 54,372,535 | |
| Standard Deviation | 66,431,531 | |
| Sample Variance | 4413.1T | |
| Range | 215.8M | |
| R-Value | (0.14) | |
| Mean Square Error | 4609.6T | |
| R-Squared | 0.02 | |
| Significance | 0.58 | |
| Slope | (1,895,412) | |
| Total Sum of Squares | 70610.4T |
Puma Total Stockholder Equity History
About Puma Biotechnology Financial Statements
Investors use fundamental indicators, such as Puma Biotechnology's Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Puma Biotechnology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 130.3 M | 69.2 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Puma Biotechnology Correlation against competitors. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.34) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.